SAN FRANCISCO, May 22, 2025 -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a collaboration agreement with Mayo Clinic. The agreement provides OncoSwab with access to clinical research expertise and know-how to support the development of its nasal swab-based diagnostic platform.
The collaboration centers on enabling clinical validation of OncoSwab's lead diagnostic test, which utilizes genomic biomarkers from nasal fluid to detect lung cancer and expanding the technology into additional indications.
"Our goal is to deliver accurate, accessible diagnostics that empower clinicians to detect cancer earlier and with greater ease" said Andrea Stephany Díaz, co-founder and CEO of OncoSwab.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
About OncoSwab
OncoSwab is a clinical-stage diagnostics company pioneering non-invasive molecular testing for early cancer detection. Its platform harnesses nasal swab sampling combined with biomarker analysis to deliver rapid, accessible, and patient-friendly testing solutions. The company is currently conducting multi-center clinical trials and preparing for regulatory advancement in the United States and Europe.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
